WallStreetZenWallStreetZen

NASDAQ: KALA
Kala Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for KALA

Based on 3 analysts offering 12 month price targets for Kala Pharmaceuticals Inc.
Min Forecast
$1.50+492.89%
Avg Forecast
$2.67+954.15%
Max Forecast
$4.00+1,481.03%

Should I buy or sell KALA stock?

Based on 3 analysts offering ratings for Kala Pharmaceuticals Inc.
Hold
Strong Buy
0 analysts 0%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
1 analysts 33.33%

Be the first to know when Wall Street analysts revise their KALA stock forecasts and price targets.

KALA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Top 5%
96
BuyMaintains$2.50+888.14%2022-08-15
Northland Securities
Bottom 1%
1
BuyMaintains$4.00+1,481.03%2022-03-30
JP Morgan
Top 33%
68
Strong SellDowngrades$1.50+492.89%2022-03-30

1 of 1

Forecast return on equity

Is KALA forecast to generate an efficient return?

Forecast return on assets

Is KALA forecast to generate an efficient return on assets?
Company
-62.03%
Industry
14.1%
KALA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KALA earnings per share forecast

What is KALA's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.77
Avg 2 year Forecast
-$0.60
Avg 3 year Forecast
-$0.70

KALA revenue forecast

What is KALA's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$38.5M+359.02%
Avg 2 year Forecast
$26.4M+214.47%
Avg 3 year Forecast
$43.2M+414.59%
KALA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

KALA revenue growth forecast

How is KALA forecast to perform vs Biotechnology companies and vs the US market?
Company
64.97%
Industry
23.75%
Market
8.46%
KALA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
KALA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

KALA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KALA$0.25$2.67+954.15%Hold
MITO$0.31$1.50+380.77%Buy
ERYP$0.60N/AN/AHold
BVXV$1.00$7.00+600.00%Strong Buy
ALRN$0.21$1.00+385.44%Buy

Kala Pharmaceuticals Stock Forecast FAQ

Is Kala Pharmaceuticals Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: KALA) stock is to Hold KALA stock.

Out of 3 analysts, 0 (0%) are recommending KALA as a Strong Buy, 2 (66.67%) are recommending KALA as a Buy, 0 (0%) are recommending KALA as a Hold, 0 (0%) are recommending KALA as a Sell, and 1 (33.33%) are recommending KALA as a Strong Sell.

If you're new to stock investing, here's how to buy Kala Pharmaceuticals stock.

What is KALA's earnings growth forecast for 2022-2024?

(NASDAQ: KALA) Kala Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.42%.

Kala Pharmaceuticals's earnings in 2022 is -$136,747,000.On average, 2 Wall Street analysts forecast KALA's earnings for 2022 to be -$56,370,268, with the lowest KALA earnings forecast at -$89,313,931, and the highest KALA earnings forecast at -$23,426,605. On average, 2 Wall Street analysts forecast KALA's earnings for 2023 to be -$43,924,884, with the lowest KALA earnings forecast at -$48,317,372, and the highest KALA earnings forecast at -$38,800,314.

In 2024, KALA is forecast to generate -$51,245,698 in earnings, with the lowest earnings forecast at -$51,245,698 and the highest earnings forecast at -$51,245,698.

What is KALA's revenue growth forecast for 2022-2024?

(NASDAQ: KALA) Kala Pharmaceuticals's forecast annual revenue growth rate of 64.97% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.75%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.46%.

Kala Pharmaceuticals's revenue in 2022 is $8,395,000.On average, 4 Wall Street analysts forecast KALA's revenue for 2022 to be $2,821,075,675, with the lowest KALA revenue forecast at $254,032,246, and the highest KALA revenue forecast at $5,014,757,590. On average, 1 Wall Street analysts forecast KALA's revenue for 2023 to be $1,932,694,896, with the lowest KALA revenue forecast at $1,932,694,896, and the highest KALA revenue forecast at $1,932,694,896.

In 2024, KALA is forecast to generate $3,162,591,648 in revenue, with the lowest revenue forecast at $3,162,591,648 and the highest revenue forecast at $3,162,591,648.

What is KALA's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: KALA) forecast ROA is -62.03%, which is lower than the forecast US Biotechnology industry average of 14.1%.

What is KALA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year KALA price target, the average KALA price target is $2.67, with the highest KALA stock price forecast at $4.00 and the lowest KALA stock price forecast at $1.50.

On average, Wall Street analysts predict that Kala Pharmaceuticals's share price could reach $2.67 by Aug 15, 2023. The average Kala Pharmaceuticals stock price prediction forecasts a potential upside of 954.15% from the current KALA share price of $0.25.

What is KALA's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: KALA) Kala Pharmaceuticals's current Earnings Per Share (EPS) is -$1.96. On average, analysts forecast that KALA's EPS will be -$0.77 for 2022, with the lowest EPS forecast at -$1.22, and the highest EPS forecast at -$0.32. On average, analysts forecast that KALA's EPS will be -$0.60 for 2023, with the lowest EPS forecast at -$0.66, and the highest EPS forecast at -$0.53. In 2024, KALA's EPS is forecast to hit -$0.70 (min: -$0.70, max: -$0.70).

What is KALA's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: KALA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.